Synthesis of α-amyrin derivatives and their in vivo antihyperglycemic activity

European Journal of Medicinal Chemistry

Volumn 44, Issue 3, 2009, Pages 1215-1222

  Narender, T ^a   Khaliq, T ^a   Singh, A B ^a   Joshi, M D ^a   Mishra, P ^a   Chaturvedi, J P ^a   Srivastava, A K ^a   Maurya, R ^a   Agarwal, S C ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Amyrin acetate; Amyrin ester derivatives; Antihyperglycemic activity; STZ S model

Indexed keywords

2 (2,4 DINITROPHENYL) 4 (2 NITROPHENYL) 1 (4,4,6A,6B,8A,11,12,14B OCTAMETHYL 1,2,4A,5,6,6A,7,8,8A,9,10,11,12,12A,14,14A HEXADECAHYDROPICEN 3 (4H,6BH,14BH) YLIDENE) THIOSEMICARBAZIDE; 2 (4,4,6A,6B,8A,11,12,14B OCTAMETHYL 1,2,3,4,4A,5,6,6A,6B,7,8,8A,9,10,11,12,12A,14,14A,14B ICOSAHYDROPICEN 3 YLOXY)CARBONYLBENZOIC ACID; 4 (4,4,6A,6B,8A,11,12,14B OCTAMETHYL 1,2,3,4,4A,5,6,6A,6B,7,8,8A,9,10,11,12,12A,14,14A,14B ICOSAHYDROPICEN 3 YLOXY) 4 OXOBUTANOIC ACID; 4,4,6A,6B,8A,11,12,14B OCTAMETHYL 1,2,3,4,4A,5,6,6A,6B,7,8,8A,9,10,11,12,12A,14,14A,14B ICOSAHYDROPICEN 3 OL; 4,4,6A,6B,8A,11,12,14B OCTAMETHYL 1,2,3,4,4A,5,6,6A,6B,7,8,8A,9,10,11,12,12A,14,14A,14B ICOSAHYDROPICEN 3 YL 2 (4 METHOXYPHENYL)ACETATE; 4,4,6A,6B,8A,11,12,14B OCTAMETHYL 1,2,3,4,4A,5,6,6A,6B,7,8,8A,9,10,11,12,12A,14,14A,14B ICOSAHYDROPICEN 3 YL 2 BENZAMIDOACETATE; 4,4,6A,6B,8A,11,12,14B OCTAMETHYL 1,2,3,4,4A,5,6,6A,6B,7,8,8A,9,10,11,12,12A,14,14A,14B ICOSAHYDROPICEN 3 YL 2 BROMOPROPANOATE; 4,4,6A,6B,8A,11,12,14B OCTAMETHYL 1,2,3,4,4A,5,6,6A,6B,7,8,8A,9,10,11,12,12A,14,14A,14B ICOSAHYDROPICEN 3 YL 2 METHYLBUT 2 ENOATE; 4,4,6A,6B,8A,11,12,14B OCTAMETHYL 1,2,3,4,4A,5,6,6A,6B,7,8,8A,9,10,11,12,12A,14,14A,14B ICOSAHYDROPICEN 3 YL 2,5 DIMETHYLBENZOATE; 4,4,6A,6B,8A,11,12,14B OCTAMETHYL 1,2,3,4,4A,5,6,6A,6B,7,8,8A,9,10,11,12,12A,14,14A,14B ICOSAHYDROPICEN 3 YL 4 CHLOROBENZOATE; 4,4,6A,6B,8A,11,12,14B OCTAMETHYL 1,2,3,4,4A,5,6,6A,6B,7,8,8A,9,10,11,12,12A,14,14A,14B ICOSAHYDROPICEN 3 YL 4 NITROBENZOATE; 4,4,6A,6B,8A,11,12,14B OCTAMETHYL 1,2,3,4,4A,5,6,6A,6B,7,8,8A,9,10,11,12,12A,14,14A,14B ICOSAHYDROPICEN 3 YL 5 OXO 5 PHENYLPENTANOATE; 4,4,6A,6B,8A,11,12,14B OCTAMETHYL 1,2,3,4,4A,5,6,6A,6B,7,8,8A,9,10,11,12,12A,14,14A,14B ICOSAHYDROPICEN 3 YLISOQUINOLINE 1 CARBOXYLATE; 4,4,6A,6B,8A,11,12,14B OCTAMETHYL 1,2,3,4,4A,5,6,6A,6B,7,8,8A,9,10,11,12,12A,14,14A,14B ICOSAHYDROPICEN 3 YLNICOTINATE; 4,4,6A,8A,11,12,14B HEPTAMETHYL 1,2,3,4,4A,5,6,6A,6B,7,8,8A,9,10,11,12,12A,14,14A,14B ICOSAHYDROPICEN 3 YL 4,4,6A,6B,8A,11,12,14B OCTAMETHYL 1,2,3,4,4A,5,6,6A,6B,7,8,8A,9,10,11,12,12A,14,14A,14B ICOSAHYDROPICEN 3 YLSUCCINATE; ALPHA AMYRIN; ALPHA AMYRIN DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE; SUCROSE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERGLYCEMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SYNTHESIS; EXPERIMENTAL MODEL; FICUS RACEMOSA; GLUCOSE BLOOD LEVEL; MALE; MORACEAE; NONHUMAN; RAT; STREPTOZOCIN DIABETES;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; HYPOGLYCEMIC AGENTS; MAGNETIC RESONANCE SPECTROSCOPY; OLEANOLIC ACID; RATS; SPECTROMETRY, MASS, FAST ATOM BOMBARDMENT; SPECTROPHOTOMETRY, INFRARED; STREPTOZOCIN;

EID: 60549101884     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2008.09.011     Document Type: Article

References (29)

1. ADA. Screening for diabetes. Diabetes Care 12 (1989) 588-590
2. Zimmet P.Z. Kelly west lecture 1991: challenges in diabetes epidemiology - from west to the rest. Diabetes Care 15 (1992) 232-252
3. Amos A.F., McCarty D.J., and Zimmet P.Z. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet. Med. 14 (1997) S7-S85
4. King H., Aubert R., and Herman W. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21 (1998) 1414-1431
5. Bailey C.J., and Day C. Traditional plant medicines as treatments for diabetes. Diabetes Care 12 (1989) 553-564
6. .
7. Izzo A.A., and Ernst E. Drugs 61 (2001) 2163
8. Vuksan V., Sievenpiper J.L., Xu Z., Wong E.Y., Jenkins A.L., Beljan-Zdravkovic U., Leiter L.A., Josse R.G., and Stavro M.P. Konjac-Mannan and american ginsing: emerging alternative therapies for type 2 diabetes mellitus. J. Am. Coll. Nutr. 20 (2001) 370S-380S
9. Kuroda M., Mimaki Y., Sashida Y., Mae T., Kishida H., Nishiyama T., Tsukagawa M., Konishi E., Takahashi K., Kawada T., Nakagawa K., and Kitahara M. Phenolics with PPAR-γ ligand- binding activity obtained from licorice (Glycyrrhiza uralensis roots) and ameliorative effects of glycyrin on genetically diabetic KK-Ay mice. Bioorg. Med. Chem. Lett. 13 (2003) 4267-4272
10. Ng T.B., Wong C.M., Li W.W., and Yeung H.W. Insulin-like molecules in Momordica charantia seeds. J. Ethnopharmacol. 15 (1986) 107-117
11. Matsuda H., Murakami T., Yashiro K., Yamahara J., and Yoshikawa M. Antidiabetic principles of natural medicines IV. Aldose reductase and α- glucosidase inhibitors from the roots of Salacia oblonga wall. (Celastraceae): structure of a new friedelane type triterpene, kotalagenin 16-acetate. Chem. Pharm. Bull. 47 (1999) 1725-1729
12. Cooper E.J., Hudson A.L., Parker C.A., and Morgan N.G. Effects of the β-carbolines, harmane and pinoline on insulin secretion from isolated human islets of Langerhans. Eur. J. Pharm. 482 (2003) 189-196
13. Werner E.A., and Bell J. CCXIV - the preparation of methylguanidine and of ββ-dimethylguanidine by the interaction of dicyanodiamide, and methyl ammonium and dimethylammonium chlorides respectively. J. Chem. Soc., Trans. 1 21 (1922) 1790-1794
14. 1-alkyl- and aralkylbiguanides. J. Am. Chem. Soc. 81 (1959) 3728-3736
15. Narender T., Shweta S., Tiwari P., Reddy K.P., Khaliq T., Prathipati P., Puri A., Srivastava A.K., Chander R., Agarwal S.C., and Raj K. Antihyperglycemic and antidyslipidemic agent from Aegle marmelos. Bioorg. Med. Chem. Lett. 17 (2007) 1808-1811
16. The Wealth of India. Raw Materials vol. 4 (1952), Council of Scientific and Industrial Research, New Delhi pp. 35-36
17. Nadkarni K.M., Nadkarni A.K., and Chopra R.N. Indian Materia Medica vol. 1 (1976), Popular Prakashan, Bombay pp. 548-550
18. Khan N., and Sultana S. Chemomodulatory effect of Ficus racemosa extract against chemically induced renal carcinogenesis and oxidative damage response in Wistar rats. Life Sci. 77 (2005) 1194-1210
19. Mandal S.C., Maity T.K., Das J., Pal M., and Saha B.P. Hepatoprotective activity of Ficus racemosa leaf extract on liver damage caused by carbon tetrachloride in rats. Phytother. Res. 13 (1999) 430-432
20. Chopra R.N., Chopra I.C., Hand K.L., and Kapur L.D. Indigenous Drugs of India. second ed. vol. 508 (1958), Academic Publishers, Calcutta p. 674
21. Kirtikar K.R., and Basu B.D. Indian Medicinal Plants. second ed. vol. 3 (1975) pp. 2327-2328
22. Mandal S.C., Mukherji P.K., Saha K., Das J., Pal M., and Saha B.P. Hypoglycemic activity of Ficus racemosa L.(Moraceae) leaves in streptozotocin-induced diabetic rats. Nat. Prod. Sci. 3 (1997) 38-41
23. Bhaskara R.R., Murugesan T., Sinha S., Saha B.P., Pal M., and Mandal S.C. Glucose lowering efficacy of Ficus racemosa bark extract in normal and alloxan diabetic rats. Phytother. Res. 16 (2002) 590-592
24. Randle P.J., Kerby A.L., and Espinal J. Mechanisms decreasing glucose oxidation in diabetes and starvation: role of lipid fuels and hormones. Diabetes Metab. Rev. 4 (1988) 623-638
25. Thiebaud D., DeFronzo R.A., Jacot E., Golay A., Acheson K., Maeder E., Jequier E., and Felber J.P. Effect of long chain triglyceride infusion on glucose metabolism in man. Metabolism 31 (1982) 1128-1136
26. Garg A., and Grundy S.M. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 264 (1990) 723-726
27. Fulcher G., Catalano C., Walker M., Farrer M., Thow J., Whately-Smith C., and Alberti K. A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus. Diabet. Med. 9 (1992) 908-914
28. Giugliano D. Insulin resistance, metabolic diseases and diabetic complications. Int. Congr. Ser 231 (1999) 1177
29. UK Prospective Diabetes (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853